Group A for Carcinoma, Renal Cell

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Arizona, Tucson, AZ
Carcinoma, Renal Cell+5 More
Social Support Network Intervention - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This project will develop and pilot test social support intervention for an underserved population, Hispanics in Arizona, who have high rates of kidney and liver cancer to improve health equity. The investigators will incorporate caregivers (family members) and other individuals in a patient's social network in survivorship, who are especially critical to quality cancer care. Caregivers provide more than half the care to cancer survivors and are often instrumental in facilitating the survivor to receive the care needed and adhere to guidelines. Through this project, the investigators will be able to leverage the resources of the Cancer Heath Equity Research Center (e.g., community outreach) to develop an intervention that has the potential for scalability and reach and recruit a sufficient sample across the target catchment area (including rural participants who may live near the US-Mexico border).

Eligible Conditions

  • Carcinoma, Renal Cell
  • Renal Cell Adenocarcinoma
  • Hepatocellular Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 3 Secondary · Reporting Duration: 6-months post enrollment (end of intervention), 12-months, and 18-months

6-months post enrollment (end of intervention)
Participant adherence to the intervention
6-months post enrollment (end of intervention) and 12-months
Mean and median time to treatment initiation in the control vs. intervention group
6-months post enrollment (end of intervention), 12-months, and 18-months
Proportion of patients who attend a follow-up imaging assessment after their surgery with hepatologists or urologists in control vs. intervention group
Proportion of patients who attend a scheduled appointment after their surgery with hepatologists or urologists in control vs. intervention group
6-months post enrollment (end of the intervention)
Study retention
9-months post enrollment
Acceptability of the intervention
Completeness of data collection
Screening and enrollment
Screening and enrollment figures

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Patient Navigation
1 of 2
Group A
1 of 2
Active Control
Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: Group A · No Placebo Group · N/A

Group A
Behavioral
Experimental Group · 1 Intervention: Social Support Network Intervention · Intervention Types: Behavioral
Patient Navigation
Behavioral
ActiveComparator Group · 1 Intervention: Control (Patient Navigation Service) · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6-months post enrollment (end of intervention), 12-months, and 18-months
Closest Location: University of Arizona · Tucson, AZ
Photo of az university of arizona  1Photo of az university of arizona  2Photo of tucson  3
2002First Recorded Clinical Trial
3 TrialsResearching Carcinoma, Renal Cell
240 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are eligible if you have a diagnosis of primary kidney and liver cancer through imaging assessment with CT or MRI at BUMC.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.